These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26569322)

  • 1. Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.
    Lozano-Maneiro L; Puente-García A
    J Clin Med; 2015 Nov; 4(11):1908-37. PubMed ID: 26569322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of RAAS blockade on the progression of diabetic nephropathy.
    Roscioni SS; Heerspink HJ; de Zeeuw D
    Nat Rev Nephrol; 2014 Feb; 10(2):77-87. PubMed ID: 24296623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH; Fu P
    Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
    Wong J
    Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
    Majewski C; Bakris GL
    Curr Diab Rep; 2016 Apr; 16(4):24. PubMed ID: 26879307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
    Malek V; Suryavanshi SV; Sharma N; Kulkarni YA; Mulay SR; Gaikwad AB
    Rev Physiol Biochem Pharmacol; 2021; 179():31-71. PubMed ID: 32979084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
    Pichler RH; de Boer IH
    Curr Diab Rep; 2010 Aug; 10(4):297-305. PubMed ID: 20532701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study.
    Kovarik JJ; Kaltenecker CC; Domenig O; Antlanger M; Poglitsch M; Kopecky C; Säemann MD
    Diabetes Ther; 2021 Sep; 12(9):2485-2498. PubMed ID: 34351585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
    Chrysant SG; Chrysant GS
    Curr Hypertens Rep; 2015 Jan; 17(1):511. PubMed ID: 25447989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
    Bakris GL; Weir MR
    Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential RAAS blockade: is it worth the risk?
    Persson F; Rossing P
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):159-65. PubMed ID: 24602465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disputes in the Treatment of Diabetic Nephropathy: The Dual Blockade of Renin-Angiotensin System.
    Grolla E; Bonanni L; Cutolo A; Presotto F; Dalla Vestra M
    Exp Clin Endocrinol Diabetes; 2016 Jun; 124(6):361-6. PubMed ID: 27219891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.